Argosy Investors Q4 Moves: New Positions and Exits
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy NVO?
Source: seekingalpha
- New Investment Position: Argosy Investors acquired shares in Floor & Décor (FND) during Q4, noting that the company's current EBIT margins are approximately 30% below pre-COVID long-term levels, and anticipates margins will scale towards the low-to-mid-teens as the store base expands, enhancing profitability and market competitiveness.
- Exit from Unfavorable Investment: The fund sold its position in Novo Nordisk (NVO) after a brief holding period due to findings from further due diligence indicating a disadvantageous competitive situation, demonstrating caution and flexibility in investment decisions.
- Increased Confidence in Holdings: Argosy also strengthened its position in Endava (DAVA) during Q4, believing that its share price performance is largely company-specific and that there is a significant chance of mean reversion if DAVA can demonstrate inflecting organic revenue growth, indicating confidence in its future growth potential.
- Market Dynamics Insight: In analyzing market dynamics, Argosy is attentive to Novo Nordisk's competitive landscape and market pressures, particularly in light of positive mid-stage trial results for its obesity drug in China, showcasing keen insights into industry trends.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 39.150
Low
42.00
Averages
54.67
High
70.00
Current: 39.150
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk to Launch Oral Ozempic in the U.S.
- Clinical Trial Success: Novo Nordisk announced that its oral version of Ozempic met its primary target in late-stage trials for children and adolescents, indicating the drug's potential in diabetes and weight management, which may further solidify its dominant position in the GLP-1 market.
- Market Expansion Opportunity: The pill form of semaglutide may be more acceptable to younger patients, particularly those who prefer pills over injections, thereby broadening Novo Nordisk's customer base and increasing market share.
- Regulatory Preparation and Commercialization: While specific trial details have not been released, the positive results will support Novo Nordisk's regulatory filings and commercialization preparations, expected to create new revenue growth opportunities for the company.
- Intensifying Market Competition: Amidst increasing competition in the obesity and diabetes therapy market, this move by Novo Nordisk could not only attract more young patients but also invite greater regulatory scrutiny, with investors keenly watching for regulatory deadlines and product launch details.
See More
Hims & Hers Expands GLP-1 Treatment Options on Platform
- Product Line Expansion: Hims & Hers has added Eli Lilly's Zepbound, Mounjaro, and Foundayo GLP-1 treatments to its platform, enhancing user choice and strengthening its competitive position in the telehealth market.
- Membership Pricing: Access to these treatments requires a membership fee of $39 for the first month and $149 thereafter, ensuring a steady revenue stream for the company while attracting more customers.
- Positive Market Reaction: Shares of Hims & Hers rose nearly 4% in opening trade following the announcement of the new offerings, indicating investor confidence in the company's strategic direction and growth potential.
- High Retail Sentiment: Retail sentiment on Stocktwits around Hims & Hers is trending in the 'extremely bullish' territory, with users expressing optimism about the stock's potential run-up before the next earnings report, reflecting a positive outlook on the company's future.
See More
Novo Nordisk's Stock Plunge: An Opportunity Amidst Panic
- Stock Plunge Analysis: Novo Nordisk's stock has plummeted 72% from its peak, reflecting investor panic over rising competition rather than a fundamental deterioration of the company's performance, indicating an overreaction to its future growth prospects.
- Increased Competitive Pressure: The emergence of Eli Lilly's dual-agonist molecule, which appears to outperform Novo on weight-loss metrics, has raised doubts about Novo's competitive edge, leading to a decline in market confidence regarding its growth outlook.
- Pipeline Depth and Market Potential: Novo's pipeline includes not only its core semaglutide but also various combination therapies, with the total addressable market for diabetes and obesity still far from saturated, indicating a vast potential customer base.
- Valuation Reset Opportunity: Currently, Novo trades at a significantly compressed forward P/E ratio, with the market pricing in a scenario of rapid market share loss; however, clinical data does not support this pessimistic outlook, presenting a buying opportunity for long-term investors.
See More
Novo Nordisk's Stock Plunge: Analyzing the Causes
- Increased Competition: Novo Nordisk's stock has plummeted over 72% from its peak, primarily due to the emergence of competitors like Eli Lilly, which has shaken investor confidence in its future growth and triggered panic selling.
- Growth Deceleration Warning: As manufacturing capacity increased, Novo's quarterly growth rates fell from triple digits to double digits, leading Wall Street to overreact by interpreting this as a sign of fundamental deterioration rather than healthy market maturation.
- Untapped Market Potential: Despite competition, the diabetes and obesity market for Novo remains unsaturated, with global GLP-1 therapy penetration in the low double digits, indicating significant future growth opportunities.
- Investment Opportunity Emerges: With Novo's price-to-earnings ratio dramatically compressed, the market has priced the stock for a scenario of rapid market share loss, yet clinical data does not support this pessimistic outlook, presenting a buying opportunity for long-term investors.
See More
Stock Index Futures Decline; Four Stocks to Watch
- Honeywell's Mixed Results: Honeywell International (HON) fell 7% in premarket trading after reporting mixed quarterly results, beating Wall Street earnings expectations but missing on revenue, with a reduced operating cash flow outlook weighing on shares, despite an 11% increase over the past 12 months.
- Lululemon's CEO Change: Lululemon (LULU) dropped 5.84% in premarket trading following the appointment of longtime Nike executive Heidi O’Neill as CEO, effective September 8, 2026, as the company struggles against increased competition from newer rivals like Vuori and Alo Yoga.
- Novo Nordisk's Drug Launch: Novo Nordisk (NVO) slipped 1.05% after announcing plans for a U.S. launch of the Ozempic pill, an oral version of its popular weight loss drug, following a successful late-stage trial for children with type 2 diabetes, achieving a 0.83% superior reduction in blood sugar compared to placebo.
- Blackstone's Strong Earnings: Blackstone (BX) reported first-quarter earnings that exceeded expectations, driven by continued inflows and market appreciation, with total assets under management reaching $1.304 trillion, surpassing the Visible Alpha consensus and indicating strong returns from its infrastructure and tactical opportunities strategies.
See More
Novo Nordisk Plans U.S. Launch of Ozempic Oral Pill
- Clinical Trial Success: Novo Nordisk's oral semaglutide demonstrated a 0.83% superior reduction in blood sugar in a late-stage trial involving children aged 10-17 with type 2 diabetes, outperforming the placebo group and confirming the drug's efficacy.
- Good Safety Profile: The oral semaglutide showed a well-tolerated safety profile consistent with previous trials, indicating high safety for use in children and adolescents, thus providing an effective treatment option for patients requiring better glycemic control.
- Market Expansion Plans: Novo Nordisk intends to file for regulatory approvals for label expansion of oral semaglutide in H2 2026, aiming to launch the Ozempic pill in the U.S. and Rybelsus in the EU, thereby expanding its market share in the targeted population.
- Industry Impact: The launch of this drug not only offers a new treatment option for children and adolescents needing better blood sugar control but also strengthens Novo Nordisk's competitive position in the GLP-1 market amid increasing competition.
See More
Novo Nordisk to Launch Oral Ozempic in the U.S.
- Clinical Trial Success: Novo Nordisk announced that its oral version of Ozempic met its primary target in late-stage trials for children and adolescents, indicating the drug's potential in diabetes and weight management, which may further solidify its dominant position in the GLP-1 market.
- Market Expansion Opportunity: The pill form of semaglutide may be more acceptable to younger patients, particularly those who prefer pills over injections, thereby broadening Novo Nordisk's customer base and increasing market share.
- Regulatory Preparation and Commercialization: While specific trial details have not been released, the positive results will support Novo Nordisk's regulatory filings and commercialization preparations, expected to create new revenue growth opportunities for the company.
- Intensifying Market Competition: Amidst increasing competition in the obesity and diabetes therapy market, this move by Novo Nordisk could not only attract more young patients but also invite greater regulatory scrutiny, with investors keenly watching for regulatory deadlines and product launch details.
See More
Hims & Hers Expands GLP-1 Treatment Options on Platform
- Product Line Expansion: Hims & Hers has added Eli Lilly's Zepbound, Mounjaro, and Foundayo GLP-1 treatments to its platform, enhancing user choice and strengthening its competitive position in the telehealth market.
- Membership Pricing: Access to these treatments requires a membership fee of $39 for the first month and $149 thereafter, ensuring a steady revenue stream for the company while attracting more customers.
- Positive Market Reaction: Shares of Hims & Hers rose nearly 4% in opening trade following the announcement of the new offerings, indicating investor confidence in the company's strategic direction and growth potential.
- High Retail Sentiment: Retail sentiment on Stocktwits around Hims & Hers is trending in the 'extremely bullish' territory, with users expressing optimism about the stock's potential run-up before the next earnings report, reflecting a positive outlook on the company's future.
See More
Novo Nordisk's Stock Plunge: An Opportunity Amidst Panic
- Stock Plunge Analysis: Novo Nordisk's stock has plummeted 72% from its peak, reflecting investor panic over rising competition rather than a fundamental deterioration of the company's performance, indicating an overreaction to its future growth prospects.
- Increased Competitive Pressure: The emergence of Eli Lilly's dual-agonist molecule, which appears to outperform Novo on weight-loss metrics, has raised doubts about Novo's competitive edge, leading to a decline in market confidence regarding its growth outlook.
- Pipeline Depth and Market Potential: Novo's pipeline includes not only its core semaglutide but also various combination therapies, with the total addressable market for diabetes and obesity still far from saturated, indicating a vast potential customer base.
- Valuation Reset Opportunity: Currently, Novo trades at a significantly compressed forward P/E ratio, with the market pricing in a scenario of rapid market share loss; however, clinical data does not support this pessimistic outlook, presenting a buying opportunity for long-term investors.
See More
Novo Nordisk's Stock Plunge: Analyzing the Causes
- Increased Competition: Novo Nordisk's stock has plummeted over 72% from its peak, primarily due to the emergence of competitors like Eli Lilly, which has shaken investor confidence in its future growth and triggered panic selling.
- Growth Deceleration Warning: As manufacturing capacity increased, Novo's quarterly growth rates fell from triple digits to double digits, leading Wall Street to overreact by interpreting this as a sign of fundamental deterioration rather than healthy market maturation.
- Untapped Market Potential: Despite competition, the diabetes and obesity market for Novo remains unsaturated, with global GLP-1 therapy penetration in the low double digits, indicating significant future growth opportunities.
- Investment Opportunity Emerges: With Novo's price-to-earnings ratio dramatically compressed, the market has priced the stock for a scenario of rapid market share loss, yet clinical data does not support this pessimistic outlook, presenting a buying opportunity for long-term investors.
See More
Stock Index Futures Decline; Four Stocks to Watch
- Honeywell's Mixed Results: Honeywell International (HON) fell 7% in premarket trading after reporting mixed quarterly results, beating Wall Street earnings expectations but missing on revenue, with a reduced operating cash flow outlook weighing on shares, despite an 11% increase over the past 12 months.
- Lululemon's CEO Change: Lululemon (LULU) dropped 5.84% in premarket trading following the appointment of longtime Nike executive Heidi O’Neill as CEO, effective September 8, 2026, as the company struggles against increased competition from newer rivals like Vuori and Alo Yoga.
- Novo Nordisk's Drug Launch: Novo Nordisk (NVO) slipped 1.05% after announcing plans for a U.S. launch of the Ozempic pill, an oral version of its popular weight loss drug, following a successful late-stage trial for children with type 2 diabetes, achieving a 0.83% superior reduction in blood sugar compared to placebo.
- Blackstone's Strong Earnings: Blackstone (BX) reported first-quarter earnings that exceeded expectations, driven by continued inflows and market appreciation, with total assets under management reaching $1.304 trillion, surpassing the Visible Alpha consensus and indicating strong returns from its infrastructure and tactical opportunities strategies.
See More
Novo Nordisk Plans U.S. Launch of Ozempic Oral Pill
- Clinical Trial Success: Novo Nordisk's oral semaglutide demonstrated a 0.83% superior reduction in blood sugar in a late-stage trial involving children aged 10-17 with type 2 diabetes, outperforming the placebo group and confirming the drug's efficacy.
- Good Safety Profile: The oral semaglutide showed a well-tolerated safety profile consistent with previous trials, indicating high safety for use in children and adolescents, thus providing an effective treatment option for patients requiring better glycemic control.
- Market Expansion Plans: Novo Nordisk intends to file for regulatory approvals for label expansion of oral semaglutide in H2 2026, aiming to launch the Ozempic pill in the U.S. and Rybelsus in the EU, thereby expanding its market share in the targeted population.
- Industry Impact: The launch of this drug not only offers a new treatment option for children and adolescents needing better blood sugar control but also strengthens Novo Nordisk's competitive position in the GLP-1 market amid increasing competition.
See More
